SPECIAL REPORT
Long-term treatment of multiple sclerosis with anti-CD20 therapies is associated with sustained efficacy and a favourable safety profile, according to new data presented at the American Academy of Neurology (AAN) annual meeting, held April 22-27 in Boston. The following summarizes some of the key data that were presented. Read More
Chitinase-3-like 1 (CHI3L1) is a glycoprotein produced by monocytes, microglia and activated astrocytes that has been proposed as a diagnostic and prognostic biomarker of progression in MS. A recent meta-analysis of 20 studies reported that CHI3L1 levels in CSF were strongly correlated with the clinical course (Floro et al. Neurol Neuroimmunol Neuroinflamm 2022;9:e1164). Levels were higher in converting clinically isolated syndrome (CIS) vs. non-converting CIS; in MS vs. CIS or healthy controls; and in PPMS vs. RRMS. Read More
Selected highlights from the American Academy of Neurology annual meeting, Boston, MA, 22-27 April 2023.
April 25 Edition
April 24 Edition
COVID-19 infections with ocrelizumab
Postpartum relapse and DMTs
NMOSD frequently misdiagnosed
sNfL after menopause
Pregnancy risks with fingolimod
Phase II study of stem-cell therapy in PMS
Low rate of ocrelizumab failure
DMT non-starters common in California
Read More
Selected highlights from the American Academy of Neurology annual meeting, Boston, MA, 22-27 April 2023.
April 26 Edition
April 24 Edition
Bruton’s tyrosine kinase (BTK) inhibitors – an update
EBV antibodies not useful for prognosis
Novel imaging studies in RIS
Read More
Selected highlights from the American Academy of Neurology annual meeting, Boston, MA, 22-27 April 2023.
April 26 Edition
April 25 Edition
Combining sNfL and cGFAP improves prognostic value
NfL/GFAP changes during anti-CD20 treatment
How is JC virus transmitted?
Does body weight affect B cell kinetics?
Hyperglycemia medications and MS risk
Read More